CDTX — Cidara Therapeutics Share News
0.000.00%
Last trade - 00:00- $6.95bn
- $6.53bn
- $1.28m
Brief: Cidara Therapeutics Announces $105 Million Private Placement
Cidara Therapeutics Inc reports results for the quarter - Earnings Summary
Cidara Therapeutics Inc expected to post a loss of $4.25 a share - Earnings Preview
Brief: Cidara Therapeutics Announces First Subjects Dosed In Phase 2B Navigate Trial Evaluating Cd388 For The Prevention Of Seasonal Influenza
Brief: Cidara Therapeutics- Estimates Will Incur Charges Of About $1.2 Million For Severance Payments And Employee Benefits, Primarily In Q4 2024
Brief: Cidara Therapeutics Restructures Workforce To Focus On Planned Clinical Development Of CD388
Cidara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Cidara Therapeutics Inc expected to post a loss of $4.10 a share - Earnings Preview
Brief: BCLS Fund III Investments Reports 9.99% Passive Stake In Cidara Therapeutics As Of July 18, SEC Filing shows
Brief: Canaan XII LP Reports 9.99% Passive Stake In Cidara Therapeutics As Of July 18, SEC filing shows
Brief: Investment Manager RA Capital Reports 9.99% Stake In Cidara Therapeutics
Brief: Cidara Therapeutics Files For Offering Of Up To 16.8 Million Common Shares By The Selling Stockholders - SEC Filing
Cidara Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Cidara Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Cidara Therapeutics Reacquires Global Development And Commercial Rights To CD388
Brief: Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma
Cidara Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cidara Therapeutics Announces Receipt Of Nasdaq Delinquency Notice
Brief: Cidara Therapeutics Identified A Material Weakness In Internal Control Over Financial Reporting